[1] El-Hattab AW, Adesina AM, Jones J, et al. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options[J].Mol Genet Metab,2015,116(1-2):4-12. DOI:10.1016/j.ymgme.2015.06.004.
[2] 北京医学会罕见病分会,北京医学会神经内科分会神经肌肉病学组,中国线粒体病协作组. 中国线粒体脑肌病伴高乳酸血症和卒中样发作的诊治专家共识[J]. 中华神经科杂志,2020,53(3):171-178. DOI:10.3760/cma.j.issn.1006-7876. 2020.03.003.
[3] El-Hattab AW, Emrick LT, Chanprasert S, et al. Mitochondria: role of citrulline and arginine supplementation in MELAS syndrome[J].Int J Biochem Cell Biol,2014,48:85-91. DOI:10.1016/j.biocel.2013. 12.009.
[4] Tetsuka S, Ogawa T, Hashimoto R, et al. Clinical features, pathogenesis, and management of stroke-like episodes due to MELAS[J].Metab Brain Dis,2021,36(8):2181-2193. DOI:10.1007/s11011-021-00772-x.
[5] Baek MS, Kim SH, Lee YM. The usefulness of muscle biopsy in initial diagnostic evaluation of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes[J].Yonsei Med J,2019,60(1):98-105. DOI:10.3349/ymj.2019.60.1.98.
[6] Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts[J].J Child Neurol,1994,9(1):4-13. DOI:10.1177/088307389400900102.
[7] 陈秉洁,蔡文红,林云峰,等. 儿童线粒体病6例临床分析[J]. 国际医药卫生导报,2020,26(24):3779-3782. DOI:10.3760/cma.j.issn.1007-1245.2020.24.017.
[8] 陈燕,曹秉振,刘磊,等. MELAS综合征的临床、影像学及病理研究[J]. 中国临床神经科学,2015,23(4):378-383.
[9] 张哲,赵丹华,刘靖,等. 线粒体脑肌病伴乳酸血症和卒中样发作190例的临床特征分析[J]. 中华神经科杂志,2016,49(3):237-242. DOI:10.3760/cma.j.issn.1006-7876. 2016.03.011.
[10] Pérez-Cruz E, González-Rivera C, Valencia-Olvera LDCG. Immunonutrition for the acute treatment of MELAS syndrome[J].Endocrinol Diabetes Nutr (Engl Ed),2021:00151-00158. DOI:10.1016/j.endinu.2021.03.004.
[11] Ohsawa Y, Hagiwara H, Nishimatsu SI, et al. Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial[J].J Neurol Neurosurg Psychiatry,2019,90(5):529-536. DOI:10.1136/jnnp-2018-317964.
[12] Koga Y, Povalko N, Inoue E, et al. Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research[J].J Neurol,2018,265(12):2861-2874. DOI:10.1007/s00415-018-9057-7.
[13] El-Hattab AW, Almannai M, Scaglia F. Arginine and citrulline for the treatment of MELAS syndrome[J]. J Inborn Errors Metab Screen, 2017, 5:10.1177/2326409817697399. DOI:10.1177/2326409817697399.
[14] Koenig MK, Emrick L, Karaa A, et al. Recommendations for the management of strokelike episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes[J].JAMA Neurol,2016,73(5):591-594. DOI:10.1001/jamaneurol.2015.5072.
[15] 韩萧迪,方方,李华,等. 儿童线粒体疾病相关癫痫62例的临床和遗传特征[J]. 中华儿科杂志,2019,57(11):844-851. DOI:10.3760/cma.j.issn.0578?1310.2019.11.006.
[16] Primiano G, Vollono C, Dono F, et al. Drug-resistant epilepsy in MELAS: safety and potential efficacy of lacosamide[J].Epilepsy Res,2018,139:135-136. DOI:10.1016/j.eplepsyres.2017.12.001.
[17] Lee HN, Eom S, Kim SH, et al. Epilepsy characteristics and clinical outcome in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)[J].Pediatr Neurol,2016,64:59-65. DOI:10.1016/j.pediatrneurol.2016.08.016.
[18] Santamarina E, Alpuente A, Maisterra O, et al. Perampanel: a therapeutic alternative in refractory status epilepticus associated with MELAS syndrome[J].Epilepsy Behav Case Rep,2019,11:92-95. DOI:10.1016/j.ebcr. 2019.01.008.
[19] Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome[J].Ann N Y Acad Sci,2008,1142:133-158. DOI:10.1196/annals.1444.011.
[20] de Laat P, Koene S, Heuvel LP, et al. Inheritance of the m.3243A>G mutation[J].JIMD Rep,2013,8:47-50. DOI:10.1007/8904_2012_159.
|